Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations
复制标题
DOI：
10.1016/j.jtho.2019.08.2503
复制
发表时间：
2019-12-01
影响因子：
20.4
通讯作者：
Joubert, Philippe
中科院分区：
文献类型：
--
作者：
Gagne, Andreanne;Wang, Emily;Joubert, Philippe
简介：靶向程序性细胞死亡1或其配体程序性死亡配体1（PD-L1）的分子彻底改变了NSCLC患者的治疗。唯一获批用于预测治疗缓解的生物标志物是通过免疫组织化学测定的PD-L1肿瘤比例评分（TPS）。根据国际肺癌研究协会（International Association for the Study of Lung Cancer）的建议，包含少于100个肿瘤细胞或超过3年的标本不应用于PD-L1检测，细胞块的可靠性尚未得到验证。方法：这项回顾性研究纳入了1249例接受PD-L1检测的连续NSCLC患者（使用克隆22 C3）在2016年9月至2017年4月期间。存在次优特征（3年样本）之间的相关性（OR = 2.46，p = 0.023）。PD-L1 TPS在细胞块和组织标本之间无统计学差异（活检OR = 0.99 [p = 0.996]和手术OR = 0.73 [p = 0.302]）。结论：我们的研究结果表明，含有少于100个肿瘤细胞或超过3年的标本可能会导致低估PD-L1状态。我们的研究结果也为使用细胞块进行PD-L1检测提供了支持，尽管还需要进一步的研究。(C)2019年国际肺癌研究协会。爱思唯尔公司出版All rights reserved.
Introduction: Molecules targeting programmed cell death 1 or its ligand programmed death ligand 1 (PD-L1) revolutionized the treatment of patients with NSCLC. The only approved biomarker for predicting treatment response is the PD-L1 tumor proportion score (TPS) determined by immunohistochemistry. According to International Association for the Study of Lung Cancer recommendations, specimens that include fewer than 100 tumor cells or are older than 3 years should not be used for PD-L1 testing and the reliability of cell blocks has yet to be validated.Methods: This retrospective study included 1249 consecutive patients with NSCLC who were tested for PD-L1 (using the clone 22C3) between September 2016 and April 2017. The associations between the presence of suboptimal characteristics (specimens with 3 years) (OR = 2.46, p = 0.023). There was no statistical difference in PD-L1 TPS between cell blocks and tissue specimens (biopsy OR = 0.99 [p = 0.996] and surgery OR = 0.73 [p = 0.302]).Conclusions: Our results suggest that specimens containing fewer than 100 tumor cells or older than 3 years may lead to an underestimation of PD-L1 status. Our findings also provide support for the use of cell blocks for PD-L1 testing, although further research is needed. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.